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Cystic fibrosis (CF) is an autosomal-recessive genetic disease 
caused by mutations in the single gene encoding the cystic fibrosis 
transmembrane conductance regulator (CFTR). CFTR is normally 
expressed on the apical plasma membrane of epithelial cells, where 
it functions as a cAMP-regulated chloride channel. CF is character-
ized by an ion and solute transport defect that, in the lungs, culmi-
nates in accumulation of dehydrated mucus, impaired mucociliary 
clearance, and chronic bacterial infection. Lung disease, the major 
cause of morbidity in CF patients, remains a significant detriment 
to a healthy life for CF patients.
Since the identification of the gene encoding CFTR, more than 
1,000 different disease-causing mutations have been identified in CF 
patients. CFTR mutations are functionally categorized by defects in 
early biosynthesis and folding (class I, II, and V), impaired chloride 
channel activity (class III and IV), or destabilization of the mature 
protein (1–3). The study of CFTR mutations has provided important 
insights into the regulation of virtually all aspects of CFTR biology 
including biosynthesis (4, 5), gating (6, 7), endocytosis (8, 9), and 
degradation (3, 10). Current therapeutic strategies are targeting the 
basic defects associated with mutant CFTR proteins with the goal of 
correcting these defects in vivo (11, 12). Consequently, the character-
ization of the processes by which CFTR is regulated in normal and 
disease states will provide critical insights into normal CFTR regula-
tion as well as aid in the development of new treatment approaches.
Here, we studied disease-causing mutations of the cytosolic N 
terminus of CFTR in order to elucidate the functional impor-
tance of this domain. Truncation of the 80–amino acid N ter-
minus disrupts normal biosynthesis, demonstrating an abso-
lute requirement for this domain (13). Zhang et al. identified 
the N terminus as a site of interaction for the cysteine string 
protein, a molecular chaperone that promotes normal CFTR 
folding (14, 15). In addition, the N terminus contains an argi-
nine-framed tripeptide sequence (residues 29–31) that func-
tions as an ER retention motif (16, 17). At the cell surface, 
CFTR is regulated by interactions with the soluble N-ethyl 
maleimide–sensitive factor attachment protein receptors 
(t-SNAREs) syntaxin 1A and SNAP23 (18, 19). The direct associa-
tion of t-SNAREs to the CFTR N terminus negatively regulates 
channel gating as well as membrane trafficking (18–24). CFTR 
channel activity can also be regulated through an intramolecu-
lar interaction between the N terminus and regulatory domain 
(R domain) (25, 26). Residues 46–63 of the CFTR N terminus are 
predicted to adopt an α-helical conformation that is able to inter-
act with the R domain. Disruption of the N terminus–R domain 
interaction decreases channel gating and may provide the mecha-
nism by which syntaxins inhibit CFTR channel activity (25–27).
To identify additional regions of the CFTR N terminus impor-
tant for channel function, we focused on the extreme N-terminal 
residues (amino acids 1–25), as they are highly conserved across 
species but to our knowledge have no known function (Figure 
1A). Furthermore, several disease-causing missense mutations in 
this region have been identified in CF patients, which suggests an 
important functional role for this region of the N terminus. While 
characterizing these CFTR mutations, we discovered a protein-
protein interaction between CFTR and filamin-A (FLN-A) that was 
disrupted by the S13F mutation. FLNs are actin-binding proteins 
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composed of 2 calponin homology domains and 24 Ig-like FLN 
repeats, the most C-terminal of which mediates dimerization (28). 
Initially identified as proteins able to crosslink actin filaments 
to form orthogonal networks (29), FLNs are now known to bind 
ion channels, receptors, and soluble signaling molecules (30). By 
forming a direct link to the underlying actin cytoskeleton, FLNs 
regulate the surface stability, membrane trafficking, and activity of 
binding partners. Here we demonstrate that FLN-A regulated the 
metabolic and plasma membrane stability of CFTR. In the absence 
of FLN-A binding, CFTR was rapidly cleared from the cell surface 
and degraded in the lysosomes. Our data highlight what we believe 
to be a novel role for the CFTR N terminus and provide insights 
into the molecular mechanism underlying the defect associated 
with the disease-causing S13F mutation.
Results
Conserved N-terminal residues are required for the biosynthetic 
maturation of CFTR. Using the CF mutations database 
(http://www.genet.sickkids.on.ca/cftr), we identified 3 
previously described missense mutations in the extreme 
N terminus of CFTR: proline 5 to leucine (P5L), serine 13 
to phenylalanine (S13F), and tryptophan 19 to cysteine 
(W19C) (31, 32). To determine whether these mutations 
would provide insights into the functional roles of the 
CFTR N terminus, we initially expressed P5L, S13F, and W19C 
CFTR in HEK293 cells and analyzed the proteins by Western 
blot. The core-glycosylated, ER form of CFTR (band B) migrates 
with an apparent molecular weight of 160 kDa. As CFTR traffics 
through the cis- and medial-Golgi, the N-glycan is processed to a 
complex oligosaccharide, decreasing the electrophoretic mobil-
ity to 180 kDa (band C) (33). Thus, monitoring the glycosylation 
state of CFTR provides a useful method to study CFTR matura-
tion and trafficking. Consistent with the results of others (33), 
WT CFTR was predominantly present as the maturely glycosyl-
ated band C at steady state (Figure 1B). Conversely, P5L and 
W19C were found only as the ER, core-glycosylated band B pro-
tein (Figure 1B). This is not surprising given the large number of 
CFTR mutations, including the most common ΔF508 mutation, 
which result in biosynthetic defects characterized by ER reten-
tion and accelerated degradation (33–35). Interestingly, however, 
S13F CFTR exhibited a clear pool of band C protein (Figure 1, B 
and C) with a significant 2.2-fold reduction in the band B/band 
C ratio relative to WT CFTR (Figure 1D). By contrast, the muta-
tion of serine 13 to another amino acid, alanine, had no effect on 
the band B/band C ratio relative to WT CFTR (Figure 1, C and 
D). We observed similar decreases in the band C protein for S13F 
CFTR in an airway epithelial cell line, 16HBE140-, which demon-
strates that the defect in S13F CFTR maturation is not cell type 
specific and is recapitulated in airway epithelial cells (Figure 1C). 
Based on the band B/band C ratio, the S13F mutation appeared 
to be distinct from the majority of CFTR mutations identified to 
date. Therefore, we sought to characterize the molecular defect 
associated with this mutation.
Figure 1
Analysis of N-terminal CFTR mutations. (A) Comparison of amino acids 
1–25 of human CFTR with those of other species. Residues conserved 
in all species are shaded black. Disease-causing missense mutations 
in CFTR identified from the CF mutation database are indicated above. 
(B and C) The indicated CFTR proteins were expressed in HEK293 
or 16HBE140- cells and analyzed by Western blot. Untransfected 
cells (UNT) served as negative controls. (D) Data from HEK293 cells 
in C was quantitated using densitometry. For all CFTR proteins, the 
level of mature band C CFTR was normalized to that of band B CFTR. 
*P < 0.01, **P < 0.001 versus WT CFTR. n = 3.
Figure 2
The S13F mutation decreases the half-life of CFTR. (A) The 
indicated CFTR proteins expressed in HEK293 cells were 
metabolically labeled and incubated in nonradioactive media 
for the indicated times. CFTR was immunoprecipitated and 
analyzed by SDS-PAGE/phosphorimager analysis. (B and C) 
Data were quantitated using ImageQuant software to examine 
CFTR maturation (B) and degradation (C). For each CFTR 
protein, data are expressed as percent of control (time 0 for B; 
band C at 4 hours for C). *P < 0.05 versus WT CFTR. n = 4.
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The S13F mutation decreases the half-life of CFTR. The decrease in 
the band B/band C ratio observed for S13F CFTR reflects either 
a defect in CFTR maturation and/or an increase in the degrada-
tion of the mature protein. Therefore, we monitored the matura-
tion and degradation in metabolic pulse-chase experiments over 
a 24-hour period. WT, S13F, and S13A CFTRs were transiently 
expressed in HEK293 cells, labeled, immunoprecipitated, and ana-
lyzed by autoradiography (Figure 2A). As an additional control, 
we included ΔF508 CFTR in these studies because this mutant 
represents a biosynthetically defective CFTR protein that fails 
to exit the ER. After 4 hours of chase, WT and S13A CFTRs were 
present almost exclusively as the mature band C, while no band 
C was observed for ΔF508 (Figure 2B). Like WT and S13A CFTR, 
S13F CFTR was clearly processed from the band B to band C pro-
tein during the first 4 hours of chase. These data indicate that the 
major defect associated with the S13F mutation does not involve 
protein folding or ER exit.
We next measured the rate of degradation of mature band C 
CFTR proteins by comparing the CFTR present after 4, 16, and 
24 hours of chase. The half-life was similar between WT and S13A 
CFTR (22.5 and 22.6 hours, respectively; Figure 2C). However, the 
half-life of S13F CFTR was reduced by more than 50% (10.8 hours; 
P < 0.05). Taken together, the results of our metabolic pulse-chase 
studies demonstrate that the S13F mutation decreases the stabil-
ity of the mature band C CFTR.
FLNs directly associate with the CFTR N terminus. We hypothesized 
that the N terminus of CFTR engages in protein-protein interac-
tions that regulate its stability, which may be affected by the S13F 
mutation. To test our hypothesis, we used affinity chromatography 
to purify proteins associated with the CFTR N terminus. CFTR pep-
tides corresponding to residues 1–25 of either WT CFTR (CFTR1–25) 
or S13F CFTR (CFTR1–25/S13F) were used as affinity ligands to purify 
CFTR interacting proteins from Calu-3 airway epithelial cell lysates. 
Bound proteins were eluted, separated by SDS-PAGE, and visualized 
by Coomassie staining. We observe several nonspecific bands associ-
ated with both CFTR1–25 and CFTR1–25/S13F. However, 2 high–molec-
ular weight bands specifically copurified with the CFTR1–25 but not 
the CFTR1–25/S13F peptides (Figure 3A). These bands were excised, 
digested in-gel with trypsin, and analyzed by matrix-assisted laser 
desorption/ionization tandem mass spectrometry (MALDI-MS/
MS). The bands were confidently identified as FLN-A and FLN-B 
(also referred to as ABP280 and ABP278, respectively), with sequence 
coverages of 34% for FLN-A and 47% for FLN-B.
Consistent with the MS data, FLN-A specifically copurified 
from Calu-3 cell lysates with the CFTR1–25 peptide as assessed by 
Western blot (Figure 3B). Moreover, purified, full-length FLN-A 
interacted with CFTR1–25, demonstrating that the interaction was 
both direct (Figure 3B) and concentration dependent (Figure 3C). 
The incorporation of the S13F mutation into the CFTR1–25 pep-
tides nearly abolished the interaction with FLN-A in these assays. 
However, CFTR1–25/S13A peptides bound to FLNs similarly to the 
CFTR1–25 peptides (Figure 3B). Taken together, these data dem-
onstrate that WT CFTR can directly interact with FLNs and that 
the S13F mutation disrupts this interaction. Thus, the reduction 
relative to WT CFTR in the band B/band C ratio observed for the 
S13F mutation, but not the S13A mutation, correlates with the 
ability to bind FLN-A in vitro.
CFTR and FLN-A associate in vivo. In order to associate within 
a biological context, CFTR and FLN-A must be coexpressed in 
the same cells and at least partially colocalize to the same sub-
cellular compartment. Therefore, we used immunoprecipitation 
to determine whether CFTR and FLN-A colocalize in relevant 
tissues. FLN-A coimmunoprecipitated with endogenous CFTR 
from Calu-3 cell lysates, but not with an IgG control (Figure 3D). 
Furthermore, FLN-A coprecipitated with WT and S13A CFTR 
expressed in HEK293 cells, but not with S13F CFTR (Figure 3E). 
Thus, the S13F mutation disrupted FLN-A binding to CFTR in 
vivo. Additionally, we found that ER-retained ΔF508 CFTR did 
not interact with FLN-A. Based on these data and the results of 
our pulse-chase studies, we speculated that FLNs do not inter-
act with CFTR in the ER. To test this hypothesis, HEK293 cells 
expressing ΔF508 CFTR were grown at 28°C. At this permissive 
temperature, we found that ΔF508 CFTR partially matured, as 
indicated by the appearance of band C (Figure 3E). As shown by 
immunoprecipitation, FLN-A copurified with rescued ΔF508 
CFTR, but not with ΔF508 CFTR from cells grown at 37°C. Thus, 
we concluded that CFTR and FLN-A interact in a post-ER com-
partment. Importantly, the S13F mutation, which disrupted FLN 
binding in pulldown and immunoprecipitation assays, provided 
Figure 3
FLNs interact with the CFTR N terminus. (A) Coomassie-stained gel 
of proteins that copurified with CFTR1–25 or CFTR1–25/S13F from Calu-3 
cell lysates. Bands identified as FLN-A and FLN-B are indicated by an 
asterisk. (B and C) FLN-A Western blots of CFTR peptide pulldowns 
from (B) Calu-3 lysates (100 μg) or (C) purified FLN-A (500 nM). Inputs 
are 5% of the total. S13A, CFTR1–25/S13A. (D) Endogenous CFTR was 
immunoprecipitated from solubilized Calu-3 membranes and analyzed 
by Western blot for CFTR or FLN-A. (E) The indicated CFTR proteins 
were expressed in HEK293 cells at 37°C or 28°C to temperature-res-
cue ΔF508 (rΔF508). CFTR was immunoprecipitated, and samples 
were analyzed by Western blot for CFTR or FLN-A. Protein molecular 
weights in kDa are shown to the left of the blots.
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us with a powerful tool to study the functional significance of 
this interaction in cells.
In polarized Calu-3 cells and primary cultures of well differenti-
ated human bronchial epithelia (WD-HBE), FLN-A was associated 
with intracellular vesicular structures and the cell cortex, where it 
was highly concentrated at the apical compartment (Figure 4, A 
and B). Likewise, CFTR was observed primarily at the apical cell 
surface in Calu-3 cells at steady state. The strong apical localiza-
tion of FLN-A in polarized epithelia suggest that CFTR and FLN-A 
may interact at or near the cell surface; however, these results do 
not preclude an interaction in an intracellular compartment.
CFTR surface expression is regulated by FLNs. Previous studies have 
shown that FLNs can regulate the cell surface expression and endo-
cytic trafficking of their transmembrane binding part-
ners (36–42). To determine whether FLNs regulate 
the plasma membrane pool of CFTR, we used CFTR 
proteins with an extracellular HA tag. The surface 
pool of CFTR was detected by immunofluorescence 
in unpermeabilized baby hamster kidney (BHK) 
cells expressing either WT, S13A, S13F, or ΔF508 
HA-CFTR. We observed significant amounts of WT 
and S13A CFTR at the cell surface, while no signal 
was observed for ΔF508 (Figure 5A). In permeabilized cells, ΔF508 
displayed a reticular staining pattern (Figure 5A) that colocalized 
with ER markers (data not shown), consistent with the intracellular 
retention of this protein. Unlike ΔF508 CFTR, we observed surface 
staining for S13F CFTR; however, the staining was greatly reduced 
compared with WT and S13A CFTR. We quantitatively analyzed 
these differences using cell surface ELISAs to measure the plasma 
membrane pool of CFTR relative to the total cellular CFTR. In agree-
ment with our observations by immunofluorescence, a substantial 
pool of WT and S13A CFTR resided on the cell surface (41.2% and 
37.8%, respectively), while no ΔF508 was observed (Figure 5B). Fur-
thermore, the surface pool of S13F CFTR was significantly less than 
that of WT and S13F CFTR (8.7%; P < 0.01) but significantly greater 
Figure 4
FLN-A localizes to the subapical membrane of air-
way epithelia. FLN-A localization was analyzed by 
immunofluorescence in (A) Calu-3 cells or (B) primary 
cultures of WD-HBEs as described in Methods. Arrow-
heads indicate the apical membrane. CFTR staining 
and purified, whole mouse IgG as a negative control 
are also shown in Calu-3 cells. Scale bars: 10 μm.
Figure 5
Surface expression of S13F CFTR is decreased. The indicated HA-CFTR proteins were expressed in BHK cells. CFTR proteins were analyzed 
by (A) immunofluorescence or (B) surface ELISA in unpermeabilized cells (surface pool) or detergent permeabilized cells (total CFTR) using HA 
antibodies as described in Methods. Scale bars: 10 μm. *P < 0.05, **P < 0.005 versus WT CFTR. n = 36.
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than that of ΔF508 CFTR (P < 0.05). Thus, in the absence of FLN 
binding, S13F CFTR localizes to the cell surface, albeit at reduced 
levels compared with WT CFTR.
The S13F mutation reflects a loss of FLN binding. We used a cationic 
lipid transfection system to introduce CFTR peptides into cells and 
disrupt the CFTR-FLN interaction in situ. Using this approach, we 
successfully delivered several fluorescent probes into cells such as 
FITC-labeled antibodies, F(ab′) fragments, and streptavidin. While 
these probes were abundantly delivered to cells, the fraction of 
transfected cells was low (<10%). The low transfection efficiency 
precluded us from using assays such as cell surface ELISA in these 
experiments. Therefore, we analyzed the effects of the peptide 
transfection using single cell assays. We examined the surface 
expression of CFTR in BHK cells stably expressing HA-CFTR that 
were transfected with a nonbiotinylated CFTR1–25 peptide cotrans-
fected with FITC-labeled F(ab′) fragments as a transfection mark-
er. We found that the transfected cells exhibited little to no CFTR 
surface expression, in contrast to untransfected cells (Figure 6, A 
and B). Importantly, this effect was not observed when the S13F 
peptide or the F(ab′) fragments alone were transfected.
In addition, we analyzed the plasma membrane pool of CFTR 
in the well characterized melanoma cell lines M2 (which lacks 
endogenous FLN-A) and A7 (which stably reexpresses FLN-A). In 
agreement with our earlier experiments, the surface expression of 
WT CFTR was clearly reduced in M2 cells compared with A7 cells 
as assessed by immunofluorescence (Figure 6C). As determined 
by ELISA, the fraction of WT CFTR on the plasma membrane 
was also significantly lower in M2 cells than in A7 cells (13.7% 
and 41.5%, respectively; Figure 6D). Thus, using several different 
approaches to manipulate the CFTR-FLN interaction, we consis-
tently found that FLN binding is required for the normal surface 
expression of CFTR.
Figure 6
Perturbations in FLN-A binding decrease the surface expression of WT CFTR. (A) The indicated CFTR peptides were introduced into BHK 
cells stably expressing WT HA-CFTR using the Pro-Ject delivery system. Cell surface CFTR was assessed by labeling unpermeabilized cells 
with HA antibodies followed by Alexa Fluor 594–labeled secondary antibodies. Transfected cells were identified by the uptake of fluorescently 
labeled F(ab′) fragments included in the transfection complexes. (B) Peptide-transfected cells were assessed for CFTR surface expression 
as described in Methods. *P < 0.05. n = 4 with 50 transfected cells counted per individual experiment. (C and D) HA-CFTR or GFP was 
expressed using adenovirus in FLN-A–replete cells (M2) or FLN-A–reexpressing cells (A7). The surface expression of CFTR was analyzed by 
immunofluorescence (C) and surface ELISA (D) as described in Figure 5. Scale bars: 10 μm.
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FLNs regulate membrane compartmentalization. We next used single 
particle tracking (SPT) experiments to further analyze the effects 
of FLN binding on plasma membrane CFTR. SPT allowed us to 
track plasma membrane CFTR at the molecular level with video 
time resolution (30 Hz). Previous studies have used this tech-
nique to observe the effects of lipid raft compartmentalization, 
membrane confinement, and cytoskeletal anchorage (43–47). 
We reasoned that SPT would allow us to observe changes in the 
membrane dynamics of CFTR associated with FLN-mediated cyto-
skeletal anchorage. Cell surface HA-CFTR proteins were labeled in 
live HeLa cells using biotinylated anti-HA antibodies followed by 
colloidal gold-conjugated anti-biotin antibodies. We then tracked 
the trajectories of single gold particles using computer-enhanced 
video microscopy. Trajectories of at least 50 different gold parti-
cles were analyzed from cells expressing WT or S13F CFTR. WT 
CFTR diffused randomly across the plasma membrane, followed 
by short periods of transient confinement (Figure 7). On average, 
WT CFTR spent 8.41% of the total recording time in transient 
confinement zones (TCZs) ranging 100–300 nm in diameter. To 
determine whether the association with FLNs is important for the 
transient confinement of CFTR, we examined S13F CFTR by SPT. 
We found that S13F CFTR exhibited significantly less transient 
confinement than WT CFTR (Figure 7). The confinement of S13F 
CFTR was reduced by more than 50% relative to WT, which reflects 
a decrease in both the number of confinements and the time spent 
in a single TCZ (Table 1). Interestingly, the diffusion coefficients 
of WT and S13F were not greatly different (3.45 ± 0.41 versus 
2.73 ± 0.71 × 10–10 cm2/s), suggesting that for CFTR, incorpora-
tion into TCZ does not alter the rate of diffusion in the mem-
brane (Table 1). Taken together, the results of our surface labeling 
and SPT experiments demonstrate that FLNs modulate both the 
expression and the confinement of CFTR at the plasma mem-
brane. Furthermore, these data support our hypothesis that FLNs 
play a role in the cell surface stability and spatial organization of 
CFTR by coupling the channel to the actin cytoskeleton.
S13F CFTR is rapidly cleared from the cell surface. At the plasma mem-
brane, CFTR is rapidly internalized into clathrin-coated vesicles 
and efficiently returned to the cell surface via endocytic recycling 
(13, 48–52). During the SPT experiments, we qualitatively observed 
many more S13F proteins internalized compared with WT CFTR. 
Although these proteins were not analyzed by SPT, this result 
prompted us to ask whether FLN-A binding affects the internal-
ization rate of CFTR using a modified surface ELISA. HeLa cells 
transiently expressing either WT or S13F HA-CFTR were chilled to 
4°C to block internalization and labeled with anti-HA antibodies. 
After removing excess antibodies, the cells were warmed to 37°C 
for 0, 5, 10, and 15 minutes and then fixed, labeled with IRDye-
labeled secondary antibodies, and analyzed using a LI-COR Bio-
sciences Odyssey instrument. Because the cells were not permea-
bilized, this approach allowed us to follow the loss of the surface 
pool due to internalization over time. We found that the surface 
expression of S13F decreased significantly more rapidly than that 
of WT CFTR (Figure 8). At the 5-minute time point, significant-
ly more S13F CFTR was internalized compared with WT CFTR 
(25.4% versus 13.8%; P > 0.05). This trend was more pronounced at 
the 15-minute time point, where 61.5% of S13F CFTR was cleared 
from the cell surface compared with 25.1% for WT CFTR. Thus, 
the FLN-binding mutant S13F CFTR is less stable on the cell sur-
face. Importantly, the differences observed between WT and S13F 
CFTR at the 5-minute time point likely reflect changes in internal-
ization. However, CFTR internalization did not change between 
the 10- and 15-minute time points for WT CFTR, indicating that 
recycling was occurring. Conversely, cell surface S13F CFTR con-
tinued to be lost between the 10- and 15-minute time points, con-
sistent with defects in recycling kinetics.
The accelerated degradation of S13F CFTR is primarily mediated by lyso-
somes. We next tested whether the endocytic trafficking of CFTR 
was regulated by FLNs. HeLa cells transiently expressing either WT 
or S13F HA-CFTR were chilled to 4°C to block internalization and 
labeled with anti-HA antibodies. After removing excess antibodies, 
the cells were warmed to 37°C for 2, 4, or 8 hours and then fixed, 
permeabilized, and labeled with fluorescent secondary antibod-
ies. Using the same HA-CFTR construct stably expressed in BHK 
cells, Gentzsch et al. found that internalized CFTR is localized 
with markers to early endosomes by 1 to 2 hours, late endosomes 
by 4 hours, and lysosomes by 48 hours (53). In our experiments, 
both WT and S13F CFTR exhibited partial overlap with the early 
endosome marker EEA1 and internalized transferrin at the 2-hour 
time point (data not shown). However, we observed striking dif-
Figure 7
The membrane dynamics of S13F CFTR is altered. WT and S13F 
CFTRs were analyzed by SPT in HeLa cells. Blue lines show trajec-
tory of individual CFTR proteins labeled with gold particles during a 
60-second recording. Red areas show regions of transient confine-
ment. The diffusion coefficient (D) and number of TCZs in each CFTR 
are also indicated. Scale bars: 1 μM. n = 45.
Table 1
SPT data quantitation for WT and S13F CFTR proteins
CFTR	 Diffusion	coefficient	 Relative	confinement	 TCZ	dwell
	 (×	10–10	cm2/s)	 	time	(%)	 time	(s)
WT 3.45 ± 0.41 8.41 ± 2.50 1.00 ± 0.32
S13F 2.73 ± 0.71 4.45 ± 1.16A 0.30 ± 0.03A
Values are mean ± SEM quantified from data in Figure 7. n = 45.  
AP < 0.001.
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ferences between WT and S13F CFTR at the 24-hour time points 
(Figure 9A). Consistent with the findings of Gentzsch et al. (53), 
we observed little colocalization of WT CFTR with lysosomes by 
24 hours. In contrast, we found some colocalization between S13F 
CFTR and lysosomes by 8 hours, which was more evident by 24 
hours (Figure 9A).
In our initial studies of the CFTR N-terminal mutations, we 
found that the steady-state distribution of S13F CFTR displayed 
a decrease in the mature band C protein, which reflects increased 
degradation. Additionally, S13F was prematurely sorted to lyso-
somes, which may explain why mature S13F CFTR was degraded 
more rapidly than the WT protein. Therefore, we examined the 
half-life of WT, S13F, and S13A CFTR by pulse chase in the pres-
ence of the lysosomal protease inhibitor leupeptin. Strikingly, leu-
peptin significantly increased the half-life of S13F CFTR from 13.4 
hours to 18.3 hours (Figure 9, B and C). Although leupeptin did 
Figure 8
S13F CFTR is internalized more rapidly than is WT CFTR. WT or S13F 
CFTRs were transiently expressed in BHK cells. The cell surface pool 
was labeled with HA antibodies as described in Methods. Antibody-
labeled CFTR proteins were allowed to internalize for the indicated 
times, and the disappearance of plasma membrane CFTR was moni-
tored. *P < 0.05, **P < 0.005 versus WT CFTR. n = 3 with 24 replicates 
per experiment for each condition.
Figure 9
S13F CFTR prematurely accumulates in the lysosomes, where it is degraded. (A) HA-CFTR proteins were expressed in BHK cells. The surface 
pool of CFTR was labeled with HA antibodies and allowed to internalize for the indicated times. CFTR was visualized using Alexa Fluor 488 anti-
bodies, and lysosomes were labeled with lysotracker red. Both immunofluorescent and differential interference contrast (DIC) microscopy images 
are shown. Insets show colocalization of CFTR and the lysosomal marker. Magnification, ×63; insets, ×189. (B) WT CFTR and S13F CFTRs 
were analyzed by metabolic labeling in pulse-chase experiments in the presence of lysosomal protease inhibitors (Leupeptin) or with no treatment 
(No tx). Representative gels are shown for WT CFTR and S13F CFTR. (C) Quantitation of the data in B. *P < 0.05 versus control. n = 3.
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not fully rescue S13F to the 21.9-hour half-life of WT CFTR (Fig-
ure 9, B and C), it suggests that lysosomally mediated degradation 
accounts for the majority of S13F turnover.
Discussion
Here we report the characterization of what we believe to be a novel 
protein-protein interaction between the N terminus of CFTR and 
FLN proteins that is required for the surface expression and sta-
bility of CFTR. In addition, we found that the S13F mutation in 
CFTR disrupted the interaction with FLNs, resulting in a decrease 
in both metabolic and plasma membrane stability of CFTR. To our 
knowledge, the disease-causing S13F mutation is the first missense 
mutation in CFTR found to disrupt a protein-protein interaction.
FLNs are best appreciated as structural proteins that regulate 
cellular architecture. However, FLNs are now known to directly 
interact with membrane-spanning proteins including ion chan-
nels, adhesion molecules, and G protein–coupled receptors 
(36–42, 54). Based on these studies, it is clear that FLNs stabilize 
their binding partners at the cell surface. For example, the plasma 
membrane levels of the glycoprotein Ibα (GPIbα; ref. 37), the D2- 
and D3-dopamine receptors (D2R and D3R, respectively; ref. 38), 
the inwardly rectifying potassium channel 2.1 (Kir2.1; ref. 40), 
furin (39), and the calcium-sensing receptor (CaR; ref. 42) are all 
significantly reduced in the absence of FLN-A binding. Likewise, 
we found an approximately 5-fold reduction in the cell surface 
pool of S13F CFTR relative to WT CFTR. This effect is specific to 
a loss of FLN binding, because decreased surface expression was 
observed for WT CFTR in the presence of a competitive peptide 
inhibitor or when expressed in cells lacking FLN-A (M2 cells). The 
decrease in the plasma membrane CFTR was greater for S13F in 
multiple cell types than for WT CFTR in the M2 cells. We hypoth-
esize that this difference can be accounted for by the fact that 
the S13F mutation disrupted the interaction with both FLN-A 
and FLN-B, whereas the M2 cells expressed FLN-B, which may 
partially compensate for the loss of FLN-A.
The decrease in CFTR surface expression coincides with altered 
plasma membrane mobility and increased endocytosis. Consis-
tent with the findings of Bates et al. (55), we found that CFTR 
was highly mobile on the cell surface, where it underwent peri-
ods of diffusion followed by brief transient confinements. For 
S13F CFTR, the partitioning of CFTR into confinement zones 
was significantly reduced (approximately 50%). Previous studies 
have shown that transient confinement may represent either cyto-
skeletal anchorage and/or partitioning into lipid microdomains 
(56). However, because cholesterol depletion has a minor effect on 
CFTR transient confinement (47), we favor the hypothesis that 
FLN is involved in either directly tethering CFTR to the cytoskel-
eton and/or creating a cytoskeletal meshwork that confines gold-
labeled CFTR by steric interactions with its cytoplasmic domain. 
Studies from our lab and others have shown that the C terminus 
of CFTR also interacts with the cytoskeleton via sodium-hydro-
gen exchanger regulatory factor (NHERF) proteins and ezrin (57, 
58). We predict that cytoskeletal interactions with the CFTR C 
terminus likely account for the residual membrane confinements 
observed for S13F CFTR. In addition, we observed increased endo-
cytosis of S13F CFTR from the plasma membrane relative to the 
WT protein. This result is consistent with the findings for other 
FLN-binding proteins such as furin (39), the calcitonin receptor 
(41), and the prostate-specific membrane antigen (PSMA; ref. 36) 
that display accelerated internalization in cells lacking FLN-A. 
Although the mechanism is not clear, it is exciting to speculate 
that the transient confinement of CFTR in the plasma membrane 
delays its incorporation into endocytic vesicles.
We also found that the half-life of S13F was decreased compared 
with WT CFTR, suggesting a role for FLNs in the metabolic stabil-
ity of CFTR. Unlike ΔF508, P5L, or W19C, S13F CFTR displayed 
a clear pool of band C protein in both heterologous expression 
systems and epithelial cells. However, this pool was substantially 
reduced (approximately 50%) relative to WT CFTR. These results, 
together with those of our pulse-chase studies, lead us to con-
clude that a primary defect associated with the S13F mutation 
is a decrease in the stability of the mature, complex glycoslyated 
protein. Likewise, the metabolic stability was altered for other 
FLN-binding proteins when FLN-A is absent or the interaction 
is disrupted. Feng et al. report that the interaction with FLN-A 
stabilizes nacent GPIbα in the ER, which is critical for both the 
metabolic stability and the surface expression of this protein (59). 
Our findings are not consistent with this mechanism for CFTR, as 
the metabolic stability was decreased for the mature band C pro-
tein as opposed to band B CFTR. Furthermore, our observation 
that ER-retained ΔF508 did not interact with FLN-A as assessed 
by coimmunoprecipitation, but temperature-rescued ΔF508 CFTR 
did, suggests that the CFTR–FLN-A interaction likely takes place 
in a post-ER compartment.
An important consideration is the relationship between the loss 
of CFTR plasma membrane stability and the premature degrada-
tion of the channel. Previous studies have shown that increasing 
CFTR internalization or decreasing endocytic recycling do not 
necessarily affect the metabolic stability of mature CFTR. For 
example, the R31L or N287Y mutations may introduce a nonna-
tive internalization motif in CFTR and result in increased plasma 
membrane internalization (8, 9). Additionally, the deletion of the 
C-terminal PDZ binding motif results in decreased apical sur-
face expression, which reflects less efficient recycling and not a 
change in endocytosis rates (60). However, the metabolic stabil-
ity of mature CFTR was not different from that of WT in these 
studies. Sharma et al. demonstrated that CFTR proteins that are 
misfolded, however, escape the ER quality control (e.g., temper-
ature-rescued ΔF508), are not stable on the cell surface, are rap-
idly internalized, and are degraded via the proteasome (61). The 
accelerated degradation associated with the S13F mutation and 
loss of FLN binding is distinct from the mechanism proposed for 
temperature-rescued ΔF508 because the degradation of S13F is 
primarily mediated by the lysosomes. The half-life of S13F CFTR 
can be restored close to that of WT CFTR by inhibiting lysosom-
al proteases. In addition, we found that S13F accumulated in a 
lysosomal compartment much more rapidly than did WT CFTR. 
It is likely that the lysosomal targeting and degradation of S13F 
CFTR reflects alterations in endocytic trafficking as a result of the 
loss of FLN binding. Similarly, the membrane trafficking of other 
FLN-A–binding proteins including furin (39), PSMA (36), and the 
calcitonin receptor (41) are altered in FLN-A–null cells, resulting 
in the mislocalization of these proteins to various endosomal com-
partments. Thus, the decreased metabolic stability of mature S13F 
CFTR may reflect both its instability at the cell surface and defec-
tive endocytic trafficking.
Although not tested here, the interaction with FLNs may also be 
important for regulating the channel activity of CFTR at the cell 
surface. The interaction with FLN-A results in clustering of the 
Kir2.1 channels and the hyperpolarization-activated cyclic nucleo-
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tide-gated channels (HCN1) at the cell surface, thereby increasing 
current density (40, 54). Additionally, FLNs can organize multi-
protein complexes and compartmentalize regulatory factors with 
receptors and ion channels. Recent studies have shown a role for 
FLN in the organization of cAMP signaling machinery upstream 
of CFTR activation including the β2-adrenergic receptor, Gαs, and 
adenylate cyclases (62). Furthermore, electrophysiological stud-
ies have shown that in the FLN-null M2 cells, both whole-cell and 
single-channel CFTR currents are reduced in response to cAMP/
PKA activity (63). While reductions in whole-cell currents in part 
reflect less plasma membrane CFTR, the decreased openings of 
single CFTR channels suggest that FLNs directly affect gating. 
Thus, FLNs may additionally compartmentalize CFTR with rel-
evant signaling molecules.
It is therefore clear that FLNs regulate multiple aspects of CFTR 
biology. Our observations are consistent with findings in CF 
patients, which suggest that S13F is a significant disease-causing 
mutation. The clinical manifestations of CFTR mutations range 
from mild, resulting in elevated sweat chlorides, to severe, resulting 
in pulmonary defects and pancreatic insufficiency. In an individu-
al with S13F paired with a known mild mutation, T338I, elevated 
sweat chloride was the only clinical manifestation (31). However, 
a patient with the S13F mutation paired with a frame-shift muta-
tion, 2185insA, displayed symptoms of CF including elevated sweat 
chloride, Pseudomonas aeruginosa lung infection, and pancreatic 
insufficiency (32). In preliminary studies, nasal potential differ-
ence measurements from the individual with S13F/2185insA were 
consistent with a functional loss of CFTR at the cell surface, as 
little to no CFTR activity was detected (M. Knowles, unpublished 
observations). However, more individuals with S13F should be 
examined to confirm the disease severity of this mutation.
CF results from the loss of CFTR from the cell surface of epithe-
lial tissues. Because the most common disease-causing mutation 
in CFTR, ΔF508, is retained in the ER due to a folding defect, ther-
apies that allow ΔF508 to escape the ER are being intensely inves-
tigated (11, 12, 64). Importantly, multiple labs have demonstrated 
that rescued ΔF508 CFTR can reach the cell surface where it has 
chloride channel activity (4). However, ΔF508 CFTR is cleared from 
the cell surface and degraded much more rapidly than WT CFTR 
(65). Therefore, an understanding of the mechanisms that regulate 
the stability of mature CFTR will provide important insights into 
therapeutic strategies aimed at rescuing ΔF508 CFTR. It is clear 
from these previous results that the maintenance of the plasma 
membrane pool of CFTR involves a complex set of regulatory 
interactions that govern aspects of trafficking, anchoring, inter-
nalization, and endocytic recycling. Direct and indirect protein-
protein interactions with PDZ protein, clathrin subunits, small 
GTPases, myosins, and syntaxins have all been shown to regulate 
these aspects of CFTR biology (reviewed in ref. 66). Here we dem-
onstrate that FLNs are a key element of this regulatory network 
by anchoring CFTR on the plasma membrane and stabilizing the 
mature protein. In future studies, it will be important to assess 
how these accessory proteins coordinately maintain the plasma 
membrane pool of CFTR.
Methods
Plasmids. CFTR mammalian expression constructs were prepared in 
pcDNA3.1(+). All CFTR point mutants used in this study were generated 
by site-directed mutatagenesis using the QuikChange XL Kit (Stratagene) 
and sequenced at the University of North Carolina DNA sequencing facil-
ity. Exotope CFTR (referred to as HA-CFTR) was generated by introducing 
an HA tag into a modified second extracellular loop of CFTR as described 
by Gentzsch et al. (53).
Cell culture. HEK293, HeLa, and BHK cells were cultured in DMEM sup-
plemented with 10% FBS and penicillin/streptomycin. M2 and A7 cells were 
cultured as previously described (39). BHK cells stably expressing HA-CFTR 
were grown in selection media supplemented with 500 μg/ml mexthotrax-
ate. Calu-3 cells were maintained as described previously (67). WD-HBE cells 
were isolated from freshly excised bronchial specimens from normal sub-
jects and cultured as described previously (67). Isolation of WD-HBE cul-
tures was approved by the University of North Carolina Institutional Review 
Board. Transient transfections were performed using Effectene (QIAGEN) 
or Lipofectamine 2000 (Invitrogen) according to the manufacturer’s sug-
gestions. Assays were carried out 24–48 hours after transfection. HA-CFTR 
was expressed in M2 and A7 cells using adenovirus generated by the Cystic 
Fibrosis Center Molecular Biology Core Facility at an MOI of 20.
Antibodies and other reagents. CFTR monoclonal antibodies 293 and 570 
(used for Western blots) and CFTR 570 cross-linked to Protein G Dyna-
beads (Invitrogen; used for immunoprecipitation) were provided by 
J. Riordan (University of North Carolina). Cell surface labeling of 
HA-CFTR was performed using HA monoclonal antibody HA.11 
(Covance). Full-legnth FLN-A was analyzed using monoclonal antibodies 
1678 and 1680 (Chemicon International).
Affinity purification of CFTR-interacting proteins. Peptides corresponding to 
residues 1–25 of CFTR were synthesized followed by a serine-glycine-ser-
ine-gylcine (SGSG) linker region and a C-terminal lysine residue coupled 
to biotin (Genemed Synthesis and Tufts University Peptide Core Facility). 
The CFTR1–25 or CFTR1–25/S13F peptides were used to affinity purify CFTR-
binding proteins as described by Thelin et al. (67), with the following excep-
tions. Bound proteins were eluted with 100 μl of 1× Laemmli sample buffer 
and resolved by SDS-PAGE. Gels were stained with Coomassie blue per the 
University of North Carolina–Duke Michael Hooker Proteomics Center 
standard procedures (http://proteomics.unc.edu/protocol.shtml). Visible 
bands were excised and prepared for MS analysis by MALDI-MS/MS as 
described previously (68).
CFTR immunoprecipitation. CFTR immunoprecipitation experiments 
were performed as described previously (67). Briefly, CFTR was immuno-
precipitated from cell membranes solubilized in binding buffer (50 mM 
Tris-Cl, pH 7.4, 150 mM NaCl, 0.1% Triton-X 100) prepared from Calu-3 or 
HEK293 cells using the CFTR 570 antibody covalently bound to Protein-G 
Dynabeads (Invitrogen). Bound proteins were washed 4 times for 5 minutes 
per wash in binding buffer. Bound proteins were eluted with 1× Laemmli 
buffer, resolved by SDS-PAGE, and analyzed by Western blot.
Immunohistochemistry. Conditions for immunohistochemical analy-
ses in Calu-3 cells and WD-HBE cultures were as previously described 
(69, 70). All confocal microscopy was performed in the Michael Hooker 
Microscopy Facility.
Pulse-chase analysis. WT, S13F, S13A, and ΔF508 CFTRs were transient-
ly expressed in HEK293 cells. Twenty-four hours after transfection, the 
cells were starved in cysteine/methionine-free DMEM for 30 minutes. We 
incubated 250 μCi/ml 35S-promix (GE HealthCare) with the cells for an 
additional 30 minutes. The labeling media was removed, and the cells were 
chased with cold DMEM supplemented with 10% FBS and incubated at 
37°C for the chase periods indicated in Figure 2A and Figure 9B. Cells 
were recovered by incubating with 15 mM sodium citrate and pelleted by 
centrifugation. CFTR was immunoprecipitated from whole cell lysates as 
described above. Immunoprecipitates were resolved by SDS-PAGE, and the 
gels were dried and visualized by phosphorimager analysis. For lysosomal 
inhibitor studies, 10 μg/ml leupeptin was included in the culture media. All 
data were quantitated using ImageQuant TL software (GE HealthCare).
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 117   Number 2   February 2007 373
CFTR surface labeling and ELISAs. HA-CFTR proteins were transiently 
expressed in HeLa or BHK cells grown on glass coverslips (immuno-
fluorescence) or 24-well plates (ELISAs). Cells were fixed with 4% PFA, blocked 
for 2 hours in blocking buffer (PBS with 2 mg/ml BSA, 4% nonfat milk, and 
1% fish gelatin), labeled in anti-HA antibodies in blocking buffer for 2 hours, 
washed 3 times for 10 minutes per wash, and labeled with either Alexa Fluor 
488 (Immunofluorescence; Invitrogen), HRP-conjugated (ELISAs; Jackson 
ImmunoResearch Laboratories Inc.), or IRDye-680 (ELISAs; LI-COR Biosci-
ences) secondary antibodies. Surface CFTR was analyzed in the absence of 
detergents, while total CFTR was analyzed in cells permeabilized with 0.1% 
Triton-X 100. For surface ELISAs, labeled cells were incubated with the HRP 
substrate ABTS (Pierce Biotechnology) for 30 minutes at room temperature 
and analyzed by a microplate reader at 405 nm or analyzed using an Odyssey 
infrared imaging system (LI-COR Biosciences).
SPT assays. HA-CFTR was expressed in HeLa cells, and SPT experiments 
were performed as described previously (47). Briefly, cell surface CFTR 
was labeled using biotinylated HA antibodies followed by anti-biotin–con-
jugated gold (40 nm in diameter). Gold-labeled CFTR was analyzed by 
computer-enhanced video microscopy as described previously (47). CFTR 
proteins were imaged in brightfield mode for 1,800 frames/particle at 30 
Hz. Movies were analyzed by ISEE software (version 3.1; Inovision), and all 
trajectories were visually inspected to ensure correct tracking.
CFTR internalization assays. HeLa and BHK cells expressing HA-CFTR pro-
teins were chilled to 4°C on ice and incubated with HA antibodies diluted in 
serum-free DMEM (0.05 μg/μl) for 10 minutes. Unbound antibodies were 
washed off, and the cells were returned to 37°C for various times to allow 
the CFTR/antibody complexes to internalize. For immunofluorescence 
assays, cells were fixed in 4% PFA, incubated in blocking solution with 0.1% 
Triton-X 100, and labeled with Alexa Fluor 488–conjugated anti-mouse 
antibodies. Lysosomes were labeled by incubating cells in 50 nM lysotracker 
red dye (Invitrogen) for 30 minutes. For endocytosis experiments, unper-
meabilized cells were fixed in 4% PFA, incubated with IRDye-680 secondary 
antibodies, and analyzed using the Odyssey infrared imaging system.
Peptide transfection. To disrupt the CFTR-FLN interaction in situ, short 
competitive peptides were introduced into cells using a lipid delivery sys-
tem. Specifically, nonbiotinylated CFTR1–25 or CFTR1–25/S13F peptides were 
introduced into BHK cells stably expressing HA-CFTR with the Pro-Ject 
transfection system (Pierce Biotechnology). Complexes were formed by 
incubating 5 μg of CFTR peptides with 5 μl of the Pro-Ject reagent in a total 
volume of 40 μl HEPES-buffered saline (10 mM HEPES, 150 mM NaCl, 
pH 7.0). Because the peptides cannot be visualized, Alexa Fluor 488–conju-
gated F(ab′) fragments were mixed with the peptides at a molar ratio of 4:1 
[peptide/F(ab′) fragment]. Under these conditions, we achieved consistent 
delivery of the fluorescent probe to cells. However, the transfection efficiency 
was generally less than 10%. In order to analyze the effects of the CFTR 
peptides, we labeled the cell surface pool of CFTR using Alexa Fluor 594 
secondary antibodies. For each condition, the presence or absence of CFTR 
surface expression was assessed in transfected cells. For each experiment, 50 
cells were counted in a double-blind fashion with n = 4 for each condition.
Statistics. Quantitative data including densitometry, phosphorimager 
analysis, and ELISAs were analyzed by 1-way ANOVA using GraphPad 
Prism 4. Multiple comparisons were made using Tukey’s post-hoc test. 
For all graphs, error bars represent ± SEM. P values less than 0.05 were 
considered significant.
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